Has given written informed consent before any study-related activity is performed
Advanced hormone-dependent prostate cancer for which androgen deprivation therapy is indicated, and independently from this trial, Firmagon® is intended to be used for treatment
Age greater than or equal to 18 years and less than 80 years
Advanced hormone-dependent prostate cancer without any other clinically significant disorder
Easten Cooperative Oncology Group score = 2
PSA = 2 ng/mL at screening
Life expectancy of at least 12 months as per the investigator's judgement

NCT02726009_inc_T2
Qualifier
hormone-dependent
NCT02726009_inc_T3
Qualifier
Advanced
NCT02726009_inc_T4
Condition
prostate cancer
NCT02726009_inc_T5
Procedure
androgen deprivation therapy
NCT02726009_inc_T6
Drug
Firmagon
NCT02726009_inc_T7
Mood
intended
NCT02726009_inc_T8
Person
Age
NCT02726009_inc_T9
Value
greater than or equal to 18 years and less than 80 years
NCT02726009_inc_T10
Qualifier
Advanced
NCT02726009_inc_T11
Qualifier
hormone-dependent
NCT02726009_inc_T12
Condition
prostate cancer
NCT02726009_inc_T14
Measurement
Easten Cooperative Oncology Group score
NCT02726009_inc_T15
Value
= 2
NCT02726009_inc_T16
Measurement
PSA
NCT02726009_inc_T17
Value
= 2 ng/mL
NCT02726009_inc_T18
Observation
Life expectancy
NCT02726009_inc_T19
Value
at least 12 months